Knee Osteoarthritis: Exercises, GLP-1 Medications, Creatine, Supplements and Treatment Options (2026 Evidence-Based Guide)
Updated: November 2026
Knee osteoarthritis (OA) is one of the leading causes of chronic joint pain, reduced mobility and disability, particularly among older adults. It can make everyday activities such as walking, climbing stairs, getting out of a chair and standing for prolonged periods increasingly difficult.
However, a diagnosis of knee osteoarthritis does not mean that progressive loss of mobility is inevitable. Exercise, muscle strengthening, weight management, appropriate medications and informed treatment decisions can substantially improve symptoms and help preserve independence.
New developments are expanding the treatment discussion. The STEP 9 randomized clinical trial demonstrated that semaglutide improved both body weight and knee OA symptoms in people with obesity. In September 2026, the American College of Rheumatology (ACR) introduced a conditional recommendation for GLP-1 receptor agonists to help people with knee OA and obesity achieve an appropriate weight.
At the same time, emerging research on creatine and muscle preservation highlights the importance of protecting muscle during aging and weight loss. Evidence regarding joint supplements, platelet-rich plasma (PRP), stem-cell injections and arthroscopic surgery also deserves closer examination.
This guide brings together six important areas of knee health:
- Understanding knee osteoarthritis and its causes.
- Exercises that improve strength, standing ability and balance.
- GLP-1 medications, weight loss and knee pain relief.
- Muscle preservation, protein and creatine during aging.
- Joint supplements: what clinical evidence supports.
- Arthroscopy, injections, regenerative treatments and knee replacement.
Key message: The most effective approach to knee osteoarthritis is an integrated strategy. Exercise, appropriate weight management and muscle preservation remain foundational. GLP-1 medicines may provide additional benefits for eligible people with obesity, while supplements and regenerative interventions require much more cautious interpretation.
1. Understanding Knee Osteoarthritis
What is knee osteoarthritis?
Osteoarthritis is a chronic disorder affecting the entire joint. It involves changes in cartilage, underlying bone, synovial tissue, menisci, ligaments and surrounding muscles.
Healthy articular cartilage provides a smooth, low-friction surface that allows the bones to move against one another. In osteoarthritis, cartilage undergoes progressive structural and biochemical changes. The underlying bone may remodel, osteophytes (bone spurs) may develop, and inflammation of the synovial membrane can contribute to pain and swelling.
Importantly, osteoarthritis is not simply the result of mechanical wear and tear. It is a complex interaction between biological, metabolic, genetic and biomechanical factors.
Why does knee osteoarthritis develop?
There is no single cause. Several factors can increase the likelihood of developing knee OA:
- Age: Risk increases with age because of cumulative joint exposure and age-related changes in joint tissues.
- Excess body weight: Higher body weight increases mechanical loading on the knee and is associated with metabolic and inflammatory changes.
- Previous knee injury: ACL injuries, meniscal tears, fractures and other joint injuries can increase the risk of post-traumatic OA.
- Genetics: Family history and inherited differences in joint structure and tissue biology influence susceptibility.
- Repetitive occupational loading: Certain activities involving repeated heavy lifting, kneeling or squatting may contribute to joint stress.
- Joint alignment and biomechanics: Bow-legged or knock-kneed alignment can alter how forces are distributed across the knee.
- Metabolic health: Diabetes and other metabolic abnormalities are associated with OA risk and disease burden.
These factors interact. Not everyone with one or more risk factors develops symptomatic osteoarthritis.
Recognizing the symptoms
Common symptoms include:
- Knee pain during walking, standing or climbing stairs.
- Stiffness after prolonged sitting or upon waking.
- Swelling or intermittent inflammation.
- Reduced range of motion.
- Crepitus, or a grinding or crackling sensation.
- Difficulty getting up from a chair.
- A feeling of weakness or instability.
Symptoms do not always correspond closely with X-ray findings. Some people have substantial radiographic changes but relatively little pain, while others experience significant symptoms with less obvious structural abnormalities.
How is knee OA diagnosed?
Diagnosis is generally based on medical history and physical examination. Imaging may be useful when the diagnosis is uncertain, symptoms are unusual or surgical planning is being considered.
Weight-bearing knee X-rays can demonstrate joint-space narrowing, osteophytes, subchondral sclerosis and other structural changes.
MRI is not routinely necessary for straightforward knee OA. It may be appropriate when clinicians suspect another condition, such as a significant acute ligament injury, occult fracture or a potentially repairable meniscal lesion.
2. Exercise: The Foundation of Knee Osteoarthritis Management
Exercise is one of the most consistently supported interventions for knee osteoarthritis.
It may seem counterintuitive to exercise a painful joint. However, appropriately prescribed physical activity improves muscle strength, joint function, physical capacity and pain management.
Weak quadriceps and other lower-limb muscles can make everyday activities more difficult. Reduced activity can then lead to further muscle weakness, creating a cycle of pain, inactivity and functional decline.
Why strengthening matters
The quadriceps muscles at the front of the thigh are particularly important for knee function. They help control knee movement during walking, stair climbing and standing up from a chair.
The gluteal muscles, hamstrings and calf muscles also contribute to lower-limb stability and functional movement.
A balanced exercise programme should include:
- Resistance and muscle-strengthening exercises.
- Low-impact aerobic activities.
- Balance and neuromuscular training.
- Functional exercises that replicate everyday activities.
- Flexibility and range-of-motion exercises where needed.
Three practical exercises to improve standing ability and stability
Exercise 1: Sit-to-Stand
Purpose: Strengthen the quadriceps and gluteal muscles while improving the ability to rise from a chair.
Instructions:
- Choose a stable chair with a seat height that allows you to sit comfortably.
- Sit with both feet flat on the floor, approximately hip-width apart.
- Lean slightly forward from the hips.
- Push through your feet and stand up slowly.
- Pause briefly while standing.
- Lower yourself back into the chair with control.
Starting target: Begin with five repetitions and gradually progress according to comfort and ability.
Modification: Use your hands on the armrests or a stable support if necessary. A higher chair may make the exercise easier.
Exercise 2: Supported Standing Leg Strengthening
Purpose: Improve lower-limb strength and control.
Instructions:
- Stand behind a sturdy chair or beside a stable countertop.
- Hold the support lightly.
- Slowly bend one knee, lifting the heel toward the buttocks without forcing the movement.
- Pause briefly.
- Lower the foot slowly.
- Repeat on the opposite leg.
Starting target: Perform 5–10 repetitions per leg, progressing gradually.
Alternative exercises include supported heel raises, seated knee extensions and controlled step-ups, depending on symptoms and physical ability.
Exercise 3: Supported Single-Leg Balance
Purpose: Improve balance, coordination and lower-limb neuromuscular control.
Instructions:
- Stand beside a sturdy countertop or chair.
- Hold the support with one or both hands.
- Shift your weight gradually onto one leg.
- Lift the opposite foot slightly off the floor.
- Maintain the position for several seconds.
- Return to the starting position and repeat with the other leg.
Starting target: Hold for 5–10 seconds, gradually increasing the duration if safe.
Do not attempt unsupported balancing if you have significant instability or a history of falls.
Additional exercises worth incorporating
- Seated knee extensions.
- Static quadriceps contractions.
- Glute bridges.
- Supported heel raises.
- Walking on level ground.
- Stationary cycling.
- Aquatic exercise.
- Tai Chi.
Swimming and water-based exercise may be particularly helpful for people who find weight-bearing activities uncomfortable.
How much exercise is appropriate?
There is no single programme suitable for everyone. Exercise intensity, frequency and progression should reflect pain levels, baseline fitness, joint function and other medical conditions.
A reasonable starting approach for someone who is deconditioned is short exercise sessions several times per week, with gradual progression.
Some temporary discomfort may occur when beginning an exercise programme. However, severe pain, marked swelling or a sustained worsening of symptoms should prompt reassessment and modification of the programme.
People with substantial disability, recurrent falls, significant instability or severe pain should seek guidance from a physiotherapist or appropriately qualified healthcare professional.
3. GLP-1 Medications and Knee Osteoarthritis: Can Weight Loss Improve Pain and Mobility?
One of the most important developments in knee osteoarthritis research is the emerging role of glucagon-like peptide-1 (GLP-1) receptor agonists in people who have both obesity and symptomatic knee OA.
Medicines such as semaglutide and tirzepatide are primarily used for metabolic and weight-management indications. However, substantial weight reduction may also improve the mechanical and metabolic factors contributing to knee symptoms.
More importantly, a major randomized clinical trial has now demonstrated that semaglutide can improve knee pain and physical function in people with obesity and knee osteoarthritis.
What did the STEP 9 semaglutide trial show?
The STEP 9 trial, published in the New England Journal of Medicine in October 2024, enrolled 407 adults with obesity and moderate knee osteoarthritis accompanied by at least moderate pain.
Participants received once-weekly semaglutide 2.4 mg or placebo for 68 weeks. Both groups also received counselling on physical activity and a reduced-calorie diet.
Main findings at week 68:
| Outcome | Semaglutide | Placebo |
|---|---|---|
| Mean body-weight change | −13.7% | −3.2% |
| WOMAC pain-score improvement | 41.7 points | 27.5 points |
| SF-36 physical-function improvement | 12.0 points | 6.5 points |
The WOMAC pain scale was normalized to 0–100, with higher scores indicating worse pain. These figures represent improvements from baseline, not the percentage of participants who became pain-free.
Semaglutide produced significantly greater improvements in body weight, knee pain and physical function than placebo.
Importantly, the placebo group also improved. This reinforces the contribution of lifestyle counselling, physical activity, dietary changes and other factors in osteoarthritis management.
What this means: Semaglutide has randomized-trial evidence for improving knee OA symptoms in a specific population of people with obesity and symptomatic knee osteoarthritis.
However, the trial did not demonstrate cartilage regeneration, reversal of joint damage or prevention of knee replacement.
Primary reference: Bliddal H, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. New England Journal of Medicine. 2024;391:1573–1583.
Does GLP-1 treatment relieve joint pain directly, or mainly through weight loss?
This remains one of the most important unanswered questions.
Excess body weight can increase the mechanical load placed on the knee during standing, walking and other weight-bearing activities. Obesity is also associated with metabolic and inflammatory changes that may influence osteoarthritis symptoms.
Weight reduction may therefore improve knee health through several overlapping pathways:
- Reduced mechanical loading: Less body weight can reduce the forces experienced by the knee during movement.
- Improved exercise tolerance: Reduced pain may make it easier to participate in rehabilitation and strengthening exercises.
- Improved metabolic health: Changes in metabolic health and inflammatory signalling may contribute to musculoskeletal health.
- Greater mobility: Improved comfort and physical function may support a more active lifestyle.
However, STEP 9 compared semaglutide with placebo, not groups achieving identical weight loss. It therefore cannot determine how much of the additional pain improvement resulted from weight reduction versus other medication-related effects.
Why the liraglutide trial is also important
A 2021 randomized controlled trial provides an important contrasting result.
In that study, 156 people with knee OA and overweight or obesity who had first completed an eight-week diet-induced weight-loss programme were randomized to liraglutide 3 mg daily or placebo for 52 weeks.
Liraglutide helped maintain a more favorable weight trajectory. The difference in weight change between groups was approximately 3.9 kg.
However, there was no statistically significant additional improvement in knee pain measured by the KOOS pain subscale.
The trials differed in medication, study design, participants and weight-loss trajectories. They should not be regarded as directly interchangeable.
Nevertheless, the liraglutide study demonstrates why weight reduction and pain improvement should be evaluated as separate outcomes.
What does the 2026 ACR guideline recommend?
The American College of Rheumatology published updated osteoarthritis guidance on September 14, 2026, replacing its 2019 recommendations.
One of the important changes is a new conditional recommendation for GLP-1 receptor agonists in people who have both knee OA and obesity, specifically to help achieve an appropriate weight in combination with diet and exercise.
The 2026 guideline also:
- Strongly recommends exercise for knee and hip OA.
- Strongly recommends weight loss for people with OA who meet criteria for overweight or obesity.
- Conditionally recommends GLP-1 receptor agonists for weight management in people with knee OA and obesity.
- Emphasizes individualized treatment decisions and shared decision-making.
The GLP-1 recommendation is conditional, with moderate certainty of evidence. It is not a universal prescription for every person with osteoarthritis.
It also concerns weight management, not proven cartilage regeneration or direct disease modification.
Reference: American College of Rheumatology. 2026 Osteoarthritis Guideline.
Can GLP-1 medications prevent knee replacement?
An important 2026 retrospective database study examined the association between GLP-1 receptor agonist use and subsequent total knee arthroplasty among people with knee OA.
After propensity-score matching, the researchers found that three years of exposure to newer-generation GLP-1 receptor agonists, including semaglutide or tirzepatide, was associated with a 4.71-percentage-point lower cumulative incidence of total knee arthroplasty at eight years.
The reported hazard ratio was 0.72.
This is an interesting finding that warrants further investigation. However, it was an observational study, not a randomized trial designed to determine whether GLP-1 medication prevents knee replacement.
Even after statistical matching, differences between treated and untreated patients may remain. These include differences in healthcare access, treatment decisions, disease severity, weight changes and other health behaviors.
Interpretation: The study identifies an association, not proof that GLP-1 medicines prevent knee replacement, regenerate cartilage or safely eliminate the need for surgery.
Semaglutide versus tirzepatide: what do we know?
Semaglutide currently has direct randomized-trial evidence from STEP 9 demonstrating improvements in knee OA symptoms in people with obesity.
Tirzepatide has established weight-management evidence in eligible populations, but there is no direct head-to-head randomized trial establishing that it provides the same degree of knee pain improvement as semaglutide in osteoarthritis.
The observational arthroplasty study included both semaglutide and tirzepatide, but it cannot establish equivalent clinical effectiveness between the two drugs.
It is therefore important not to assume that all GLP-1 and related incretin therapies have identical knee OA benefits.
GLP-1 versus PRP versus stem cells versus knee replacement
These interventions have different objectives and should not be treated as interchangeable alternatives.
| Treatment | Primary objective | Evidence position |
|---|---|---|
| GLP-1 medication | Weight management and metabolic health | Semaglutide has randomized evidence for improved symptoms in people with obesity and knee OA. |
| PRP | Local joint intervention | Inconsistent clinical evidence; ACR strongly recommends against routine use. |
| Stem-cell injections | Proposed regenerative intervention | No established reliable cartilage regeneration; ACR strongly recommends against routine use. |
| Knee replacement | Treatment of advanced symptomatic joint damage | Established surgical option for appropriately selected patients. |
There are no definitive head-to-head randomized trials establishing that GLP-1 medication is superior to PRP or stem-cell injections for knee pain. Their treatment targets are different.
The 2026 ACR recommendations strongly advise against routine PRP and stem-cell injections for knee and hip OA. This reflects concerns about insufficient or inconsistent evidence, not proof that every future biologic treatment will be ineffective.
For more detailed analysis, see:
GLP-1 for Knee Osteoarthritis: Pain Relief, Weight Loss, PRP, Stem Cells or Surgery?
Does GLP-1 treatment need to continue indefinitely?
Obesity is often a chronic condition, and weight regain can occur after discontinuation of effective weight-management medication.
A long-term treatment plan should therefore consider maintenance, nutrition, physical activity, muscle preservation, affordability and the risks and benefits of continued medication.
For knee OA, the ideal duration of GLP-1 treatment, the best approach after discontinuation and its long-term effect on joint structure remain areas for further research.
4. Muscle Preservation, Aging, Protein and Creatine
Why muscle health matters in knee osteoarthritis
Muscle strength is an important determinant of mobility and independence.
With aging, many people experience a progressive reduction in muscle strength and, in some cases, muscle mass. This age-related condition is known as sarcopenia.
In knee OA, pain may discourage physical activity. Reduced activity can accelerate muscle deconditioning, making it more difficult to walk, climb stairs and rise from a chair.
This creates a potentially self-reinforcing cycle:
Knee pain → Reduced activity → Muscle weakness → Reduced joint function → Greater difficulty moving.
Breaking this cycle requires attention to both joint symptoms and muscle health.
Muscle preservation during GLP-1-assisted weight loss
Weight reduction can improve knee symptoms, particularly in people with excess body weight. However, weight loss involves changes in both fat mass and lean mass.
Some loss of lean tissue may accompany substantial weight reduction, including medication-assisted weight loss. This matters particularly for older adults and people who already have reduced muscle strength.
The goal should therefore not be simply to achieve a lower number on the scale. It should be to reduce excess body fat while maintaining strength, mobility and functional capacity as much as possible.
Four priorities are particularly important:
- Progressive resistance training: Stimulate muscles through appropriately adapted strengthening exercises.
- Adequate protein intake: Support muscle maintenance during periods of reduced calorie intake.
- Regular functional activity: Maintain walking ability, standing strength and balance.
- Monitor physical function: Track strength and everyday activities, not just body weight.
Creatine may be considered as an optional adjunct, but it has not been established as a treatment that prevents GLP-1-associated muscle loss.
Can creatine help aging muscles?
Creatine monohydrate is one of the most extensively studied nutritional supplements for exercise performance and muscle function.
Creatine helps regenerate adenosine triphosphate (ATP), the energy currency used by muscle cells during short-duration, high-intensity activity.
Its most established application is as an adjunct to resistance training.
What does the evidence show?
Creatine combined with resistance training:
A 2025 systematic review and meta-analysis of randomized controlled trials in older adults reported modest benefits in muscle strength and lean tissue mass when creatine was combined with resistance training.
These findings support creatine as a potentially useful adjunct to an appropriate exercise programme.
Creatine without structured exercise:
An exploratory 2026 study examined creatine supplementation in middle-aged and older adults participating in non-exercise and exercise-plus-diet interventions.
The investigators reported an increase in lean tissue mass among participants receiving creatine even without a structured exercise programme.
However, the study included only 73 participants. The non-exercise and exercise intervention groups were selected before randomization to creatine or placebo.
This is an interesting observation, but it does not establish that creatine alone prevents sarcopenia, restores physical function or protects arthritic knees.
Broader evidence from 2026:
A separate meta-analysis of 11 randomized trials found that creatine combined with resistance training produced a modest but statistically significant improvement in muscle strength. However, pooled improvements in muscle mass and physical function were not statistically significant.
Does creatine replace exercise?
No.
Even if creatine produces modest changes in lean tissue mass without structured exercise, it does not provide all the benefits of physical activity.
Exercise provides mechanical loading, neuromuscular stimulation, cardiovascular conditioning, balance training and functional practice that supplementation alone cannot reproduce.
What about creatine safety?
Creatine monohydrate is generally well tolerated in healthy adults when used appropriately. Possible effects include gastrointestinal discomfort and temporary increases in body weight related to water retention.
People with kidney disease, significant medical conditions or medications that may affect kidney function should discuss supplementation with their healthcare professional.
Creatine can also affect the interpretation of serum creatinine measurements. Healthcare professionals should know when someone is taking it.
Product quality and accurate labelling are important when choosing a supplement.
Practical conclusion: Creatine may be considered an optional adjunct for people seeking to support muscle health, particularly when combined with resistance training. It is not an established treatment for knee osteoarthritis or a proven way to prevent muscle loss during GLP-1 treatment.
Do not overlook protein intake
Adequate dietary protein is important for maintaining muscle mass, particularly during aging, illness or weight loss.
Good sources include:
- Fish and seafood.
- Eggs.
- Milk, yogurt and other dairy products.
- Chicken and other lean meats.
- Soybeans, tofu and tempeh.
- Beans and lentils.
Protein requirements should be individualized according to age, body weight, activity level, nutritional status and kidney health.
5. Joint Supplements: What Can They Actually Do?
The market for joint supplements is extensive. Glucosamine, chondroitin, collagen, turmeric, Boswellia and other products are frequently promoted for cartilage protection, inflammation reduction and joint regeneration.
However, biological plausibility and promising laboratory findings do not necessarily translate into meaningful clinical benefits.
Glucosamine and chondroitin
Glucosamine and chondroitin are among the most widely marketed joint supplements.
They are associated with cartilage structure, leading to the hypothesis that supplementation might support cartilage maintenance.
However, clinical findings have been inconsistent. The 2026 ACR guideline strongly recommends against glucosamine, chondroitin and their combination preparations for knee, hip and hand osteoarthritis.
NICE also advises against routinely offering glucosamine for osteoarthritis because convincing evidence of benefit is lacking.
There is no reliable evidence that these supplements restore lost cartilage or reliably slow structural disease progression.
Collagen peptides
Collagen is an important structural protein in cartilage, tendons, ligaments and other connective tissues.
Hydrolyzed collagen peptides and undenatured type II collagen have been studied for joint symptoms.
Some clinical studies suggest possible improvements in pain or function, but the evidence remains heterogeneous. Different products, formulations, doses and study populations make comparisons difficult.
There is currently insufficient evidence to conclude that collagen supplementation regenerates damaged knee cartilage or reverses osteoarthritis.
Curcumin and turmeric
Curcumin is a bioactive compound found in turmeric. It has demonstrated anti-inflammatory effects in experimental studies.
Some clinical trials have reported improvements in knee pain. However, the November 2026 Cochrane review concluded that turmeric may provide little or no improvement in pain, function or quality of life compared with placebo.
Important considerations include:
- Different curcumin formulations have different absorption characteristics.
- Long-term safety evidence is limited.
- Some formulations may interact with medications.
- Potential liver-related adverse effects have been reported with certain turmeric supplements.
Boswellia serrata
Boswellia is a botanical extract containing compounds that may influence inflammatory pathways.
Small clinical studies have reported possible improvements in pain and physical function, but the available evidence is limited by differences in extract standardization, dosage and study design.
It should not be considered a proven cartilage-regenerating treatment.
Omega-3 fatty acids and fish oil
Omega-3 fatty acids, particularly EPA and DHA, have anti-inflammatory biological effects.
They may have established roles in particular nutritional and cardiovascular contexts. However, this does not mean that omega-3 supplementation is an effective knee OA treatment.
The 2026 ACR guideline conditionally recommends against fish oil supplementation specifically for knee, hip and hand OA.
This recommendation should not be confused with the use of prescription omega-3 products or dietary interventions for other independently established medical indications.
Vitamin D
Vitamin D is important for bone and muscle health. Deficiency should be identified and corrected when clinically appropriate.
However, additional vitamin D in people who already have adequate levels has not consistently demonstrated meaningful improvement in knee OA symptoms or cartilage preservation.
The 2026 ACR guideline conditionally recommends against vitamin D as an osteoarthritis treatment.
This does not mean that people with vitamin D deficiency should avoid treatment. Correcting a documented deficiency remains a separate clinical objective.
What do the 2026 guidelines say about supplements?
The updated ACR recommendations provide a particularly important clarification for patients considering joint supplements.
| Intervention | 2026 ACR position for OA | Interpretation |
|---|---|---|
| Glucosamine | Strongly against | Not recommended as routine OA treatment |
| Chondroitin | Strongly against | Not recommended as routine OA treatment |
| Fish oil | Conditionally against | Insufficient justification for routine OA supplementation |
| Vitamin D | Conditionally against | Not an established OA treatment; treat deficiency separately |
| Collagen | No specific recommendation in this summary | Clinical evidence remains uncertain |
| Curcumin | No specific recommendation in this summary | Recent Cochrane assessment remains cautious |
| Boswellia | No specific recommendation in this summary | Limited clinical evidence |
The absence of a specific ACR recommendation for collagen, turmeric or Boswellia should not be interpreted as proof that these supplements are effective. Their evidence must be assessed independently.
Practical conclusion: Supplements should be viewed as optional adjuncts, not essential treatments. Their cost, potential interactions, product quality and uncertain benefits should be considered before starting them.
6. Knee Arthroscopy: When Does Surgery Actually Help?
Knee arthroscopy is a minimally invasive surgical procedure in which a surgeon inserts a small camera and specialized instruments into the knee through small incisions.
It is commonly used to investigate and treat selected knee conditions, including certain meniscal tears, loose bodies and other mechanical abnormalities.
However, the fact that arthroscopy is a common orthopedic procedure does not mean it is an effective treatment for degenerative knee osteoarthritis.
What happens during arthroscopy?
Depending on the indication, the surgeon may:
- Inspect the joint structures.
- Remove loose fragments of cartilage or bone.
- Repair selected meniscal tears.
- Remove or treat specific mechanical obstructions.
- Perform other targeted procedures when clinically indicated.
Does arthroscopy improve degenerative knee OA?
The evidence is considerably less favorable than many patients might expect.
A major BMJ clinical practice guideline published in 2017 recommended against arthroscopy for nearly all patients with degenerative knee disease.
The recommendation applies to patients with or without imaging evidence of osteoarthritis, degenerative meniscal tears, mechanical symptoms or sudden symptom onset.
Randomized trials have generally failed to demonstrate clinically important long-term advantages of arthroscopic surgery over non-operative treatment for these degenerative conditions.
When might arthroscopy be appropriate?
Arthroscopy may be appropriate for selected conditions that are different from uncomplicated degenerative knee OA.
Examples include:
- A displaced meniscal fragment causing a genuinely locked knee.
- Selected acute traumatic meniscal tears that are suitable for repair.
- A symptomatic loose body producing a mechanical obstruction.
- Septic arthritis requiring urgent joint washout.
- Other specific intra-articular conditions for which a targeted arthroscopic procedure is indicated.
It is important to distinguish a genuinely locked knee, in which physical obstruction prevents normal extension, from occasional clicking, catching or stiffness.
7. Other Evidence-Based Treatment Options
Weight management
Excess body weight increases the mechanical load on the knee. It is also associated with metabolic changes that may influence joint inflammation.
For people with overweight or obesity, weight reduction can improve pain and physical function.
The 2026 ACR guideline strongly recommends weight loss for people with knee and hip OA who meet criteria for overweight or obesity. GLP-1 receptor agonists may be considered for eligible people with knee OA and obesity as part of a broader weight-management strategy.
Weight management should be approached without compromising muscle mass. Adequate protein intake and resistance exercise are particularly important during weight loss.
Topical anti-inflammatory medications
Topical non-steroidal anti-inflammatory drugs (NSAIDs) are strongly recommended in the 2026 ACR guideline for knee OA.
They may provide pain relief with less systemic exposure than oral NSAIDs, although systemic absorption and adverse effects are still possible.
Oral NSAIDs
Oral NSAIDs may be considered when topical treatments are ineffective or unsuitable.
However, they can increase the risk of gastrointestinal bleeding, kidney injury and cardiovascular complications. Risk assessment and appropriate gastroprotection are important.
Corticosteroid injections
Intra-articular corticosteroid injections may provide short-term relief for selected patients, particularly when pain prevents participation in rehabilitation.
They should not be interpreted as cartilage-regenerating or disease-modifying treatments.
Hyaluronic acid injections
Hyaluronic acid injections have been promoted as a means of improving joint lubrication.
However, the updated ACR guideline conditionally recommends against intra-articular hyaluronic acid injections for knee and hip OA because the clinical benefits are insufficiently convincing.
Platelet-rich plasma (PRP)
PRP is made by processing a sample of a patient's blood to concentrate platelets and related biological components. It is then injected into the joint.
Platelets contain growth factors and signalling molecules that have prompted interest in tissue repair. However, biological plausibility does not establish that a treatment restores cartilage or changes the natural course of osteoarthritis.
PRP preparations vary in platelet concentration, leukocyte content, processing methods, number of injections and clinical protocols. These differences make the evidence difficult to interpret.
Although some studies report improvements in pain and function, the 2026 ACR guideline strongly recommends against routine PRP treatment for knee and hip OA.
Patients should be particularly cautious about expensive treatments marketed with guaranteed-success claims or promises to avoid knee replacement.
Stem-cell injections and regenerative medicine
Stem-cell and other cell-based interventions are often promoted as a way to repair cartilage, reduce inflammation or avoid joint replacement.
However, products differ in their source, processing, composition and proposed mechanisms. Results from one preparation cannot automatically be generalized to another.
Even when a study reports improvements in pain or function, that does not necessarily demonstrate that new, durable articular cartilage has formed.
The 2026 ACR guideline strongly recommends against routine stem-cell injections for knee and hip OA, with moderate certainty of evidence.
Patients should be skeptical of claims that these injections reliably regenerate cartilage, reverse end-stage osteoarthritis or prevent knee replacement.
8. Can GLP-1 Treatment Help Avoid Knee Replacement?
Weight loss and symptom improvement may help some patients defer surgery. However, it is not yet possible to identify reliably who will avoid knee replacement because of GLP-1 treatment.
The 2026 observational database study described earlier found a lower long-term incidence of total knee arthroplasty among people with knee OA who had received GLP-1 receptor agonists.
This finding is promising, but an association in an observational study does not establish that the medications caused the reduction.
When should someone consider knee replacement?
Joint replacement may be appropriate when pain, stiffness, impaired mobility or progressive deformity substantially affects daily life and non-surgical management has been ineffective or unsuitable.
Options such as exercise, weight management, pain medication and rehabilitation should be considered according to the patient's needs and medical circumstances.
However, there is no universal requirement to try every available injection before seeking an orthopedic opinion.
NICE advises clinicians to consider referral for joint replacement when symptoms substantially affect quality of life and non-surgical management is ineffective or unsuitable.
Importantly, people should not be excluded from referral for joint replacement solely because they have overweight or obesity.
Reference: NICE. Osteoarthritis in over 16s: diagnosis and management.
Key distinction: GLP-1 medication may help manage obesity and improve symptoms, but it should not become a reason to delay appropriate orthopedic assessment when advanced OA causes substantial disability.
9. An Integrated Knee Health Strategy
The most useful approach is not to focus exclusively on cartilage or pain. Knee health requires attention to the entire musculoskeletal and metabolic system.
The six pillars
- Joint health: Understand the disease, identify contributing factors and obtain an appropriate diagnosis.
- Muscle strength: Maintain quadriceps, gluteal, hamstring and calf strength.
- Mobility and balance: Incorporate walking, functional movements and balance training.
- Metabolic health: Address excess body weight, diabetes and other relevant metabolic risk factors. Consider GLP-1 medication when clinically appropriate.
- Nutrition: Maintain adequate protein intake and a balanced dietary pattern.
- Informed treatment decisions: Use medications, injections, supplements and surgery according to clinical indications and evidence.
A practical weekly framework
| Activity | Suggested starting framework | Main objective |
|---|---|---|
| Strength training | 2–3 sessions weekly | Preserve muscle and improve joint function |
| Walking or cycling | Short, regular sessions, gradually increased | Improve aerobic fitness and mobility |
| Balance exercises | Several short sessions weekly | Improve stability and confidence |
| Functional exercises | Sit-to-stand and supported step exercises | Improve everyday independence |
| Nutrition | Adequate protein and balanced meals daily | Support muscle and general health |
| Weight management | Individualized dietary and medical support | Reduce excess mechanical and metabolic burden |
This is an illustrative framework, not a prescribed programme. Frequency, intensity and exercise selection should be adapted to the individual's physical capacity, symptoms and medical circumstances.
Measure what matters: beyond body weight
A successful knee OA strategy should track more than weight and pain scores.
Consider monitoring:
- Pain during walking, standing and climbing stairs.
- Ability to get up from a chair.
- Walking distance and daily activity.
- Muscle strength and physical function.
- Sleep quality and participation in exercise.
- Body weight and nutritional adequacy.
- Medication adverse effects and treatment tolerability.
Improvement in weight does not guarantee parallel improvement in knee function. Conversely, improved muscle strength and mobility can provide meaningful benefits even when weight loss is modest.
10. When Should You Seek Medical Attention?
Not every painful knee is caused by osteoarthritis. Other conditions, including gout, inflammatory arthritis, infection, fractures and ligament injuries, may produce similar symptoms.
Seek urgent medical assessment if you develop:
- A suddenly hot, red and markedly swollen knee, particularly with fever or feeling unwell.
- Severe pain following an injury or inability to bear weight.
- A genuinely locked knee with inability to straighten it.
- Rapidly increasing swelling or severe instability.
Persistent or worsening pain, recurrent falls and progressive loss of mobility also warrant clinical evaluation.
11. Frequently Asked Questions
Can knee osteoarthritis be reversed?
There is currently no established treatment that reliably reverses advanced structural knee osteoarthritis or regenerates lost articular cartilage. However, symptoms and function can improve substantially with exercise, weight management and appropriate treatment.
Does walking make knee osteoarthritis worse?
Appropriately paced walking is generally beneficial. The duration and intensity should be adjusted to symptoms and physical capacity. Sudden increases in activity may aggravate symptoms, so gradual progression is preferable.
What is the best exercise for knee osteoarthritis?
There is no single best exercise. Quadriceps strengthening, sit-to-stand exercises, low-impact aerobic activity and balance training address different aspects of knee function.
Can Ozempic or Wegovy help knee osteoarthritis?
Semaglutide improved knee pain, physical function and body weight in the STEP 9 trial involving adults with obesity and symptomatic knee osteoarthritis. Wegovy is a semaglutide brand used for chronic weight management in eligible patients in the United States. Ozempic and Wegovy have different approved indications and dosing instructions. Neither should be considered an established cartilage-regenerating treatment.
Does semaglutide rebuild knee cartilage?
There is no established clinical evidence that semaglutide regenerates damaged knee cartilage in humans. The STEP 9 trial demonstrated improvements in symptoms and weight, not proven cartilage regrowth.
Is tirzepatide as effective as semaglutide for knee pain?
There is no direct head-to-head randomized trial establishing that tirzepatide provides the same degree of knee pain relief as semaglutide in osteoarthritis. Tirzepatide has evidence for weight management in eligible patients, but equivalent knee OA symptom benefits have not been established.
Can GLP-1 medication help me avoid knee replacement?
Some people may experience enough improvement in symptoms and function to postpone surgery. However, there is no reliable evidence that GLP-1 medication guarantees avoidance of knee replacement. An observational study in 2026 found an association with lower arthroplasty incidence, but causality has not been established.
Should I lose weight before seeing a knee surgeon?
Weight management may improve health and help optimize surgical preparation, but an orthopedic assessment should not automatically be postponed until a target weight is reached. Referral decisions should take account of symptom burden, expected surgical benefits and risks, and individual circumstances.
Can creatine help people with knee osteoarthritis?
Creatine may support muscle strength and lean tissue mass, particularly when combined with resistance training. However, direct clinical evidence demonstrating that creatine improves knee OA symptoms or slows joint deterioration is currently insufficient.
Should I take glucosamine and chondroitin?
The 2026 ACR guideline strongly recommends against these supplements as routine osteoarthritis treatments because convincing clinical benefits have not been established. Neither has demonstrated reliable cartilage-regenerating effects.
Is PRP better than conventional treatment?
Some studies have reported improvements following PRP injections, but results vary considerably. The updated 2026 ACR guideline strongly recommends against routine PRP treatment for knee and hip OA. It should not be promoted as a proven cartilage-regenerating therapy.
Are stem-cell injections a proven alternative to knee replacement?
No. There is insufficient evidence that current stem-cell injection treatments reliably regenerate knee cartilage or prevent joint replacement. The 2026 ACR guideline strongly recommends against their routine use for knee and hip OA.
When is knee replacement necessary?
Knee replacement may be considered when severe OA causes substantial pain and functional impairment despite appropriate non-surgical management. The decision should be based on symptoms, functional limitations, clinical assessment and individual preferences rather than X-ray findings alone.
12. Conclusion: Treat the Person, Not Just the Knee
Knee osteoarthritis is a complex whole-joint condition, but successful management requires more than focusing on cartilage deterioration.
Maintaining muscle strength, improving mobility, managing body weight and addressing metabolic health are central to preserving independence.
The STEP 9 trial has established an important role for semaglutide in improving weight and knee OA symptoms in people with obesity. The 2026 ACR guideline further recognizes GLP-1 receptor agonists as a conditional option for appropriate weight management in people with knee OA and obesity.
However, GLP-1 medicines should not be described as proven cartilage-regenerating treatments or as guaranteed ways to avoid knee replacement. Their role is best understood within a broader programme that includes exercise, muscle preservation, nutrition and individualized medical care.
Creatine is an interesting nutritional intervention with emerging evidence in aging muscle health, but its benefits should not be overstated. Joint supplements have important evidence limitations, while PRP and stem-cell injections are not recommended for routine knee OA treatment in the updated ACR guidance.
Similarly, arthroscopic surgery should not be assumed to be beneficial simply because a meniscal abnormality or degenerative change appears on imaging.
The central principle is straightforward: reduce avoidable joint stress, preserve muscle, improve metabolic health, maintain mobility and make treatment decisions based on meaningful improvements in pain, function and quality of life.
References and Further Reading
- NICE. Osteoarthritis in over 16s: diagnosis and management (NG226).
- World Health Organization. Osteoarthritis.
- NIAMS. Osteoarthritis: Symptoms, Causes and Risk Factors.
- American College of Rheumatology. 2026 Osteoarthritis Guideline.
- Bliddal H, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. New England Journal of Medicine. 2024;391:1573–1583.
- Gudbergsen H, et al. Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. American Journal of Clinical Nutrition. 2021;113:314–323.
- GLP-1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis. Regional Anesthesia & Pain Medicine. 2026.
- ACR. 2026 Update of Recommendations for the Management of Osteoarthritis of the Knee, Hip and Hand.
- Liu et al. Creatine supplementation associated with resistance training in older adults. European Review of Aging and Physical Activity (2025).
- Effects of creatine supplementation with and without exercise and diet intervention in middle-aged and older adults (2026).
- Systematic review and meta-analysis of creatine and resistance training in older adults (2026).
- Cochrane. Turmeric or its active ingredients for osteoarthritis (2026).
- Siemieniuk et al. Arthroscopic surgery for degenerative knee arthritis and meniscal tears: a clinical practice guideline. BMJ (2017).
- NHS Inform. Exercises for osteoarthritis of the knee.
Medical Disclaimer
This article is intended for general educational purposes and is not a substitute for individualized medical advice, diagnosis or treatment. Exercise programmes, medications and supplements should be selected according to individual health status and clinical circumstances.
GLP-1 receptor agonists are prescription medicines with product-specific indications, contraindications and adverse effects. They should only be used under appropriate medical supervision. Do not discontinue prescribed treatment or delay medical evaluation because of information presented here.
OneDayMD — Independent health research and evidence-based education.
Comments
Post a Comment